ACADIA Pharmaceuticals entered the second quarter of 2026 carrying two commercial products and one overdue test. NUPLAZID, the first drug approved for the hallucinations and delusions of Parkinson's disease psychosis, has carried the company for a decade but grows slowly now. DAYBUE, the first approved treatment for Rett syndrome, is the growth engine of record. The quarter that closed June 30 delivered on the commercial side - revenue rose 16% to $308 million, guidance for the full year went up, and net income widened to $31.5 million from $26.7 million a year earlier - while the company simultaneously finished enrollment on the Phase 2 portion of its remlifanserin program in Alzheimer's disease psychosis, the biggest single swing factor in the story.
The central tension is the gap between the steady commercial quarter and the binary clinical one. DAYBUE grew 30% year over year to $125 million, driving the raised DAYBUE guide of $480 to $510 million, and the company lifted total revenue guidance to $1.24 billion to $1.30 billion. NUPLAZID, by contrast, grew only 9% to $183 million, its momentum now dependent on a recently expanded sales force whose traction shows up in new-to-brand prescriptions rather than total growth. What changed: the story is no longer two products in a mature groove but one mature franchise defending share and one growth franchise plus a late-stage pipeline whose value will be marked to market when topline Phase 2 remlifanserin results land in September to October 2026.
What decides the thesis: the commercial base is de-risking even as the per-share earnings picture stays muddled by a one-time tax benefit that inflated trailing results. The investor is buying a ~4x forward price-to-sales biopharma with growing, profitable rare-disease sales, plus a free option on a potential first-in-class Alzheimer's psychosis treatment. The readout confirms or breaks that option; the commercial execution confirms or breaks the base.